About ARV-110ARV-110 is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR).

NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -- Data represent the ...

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO ...

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were ...

NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation ...

* ARVINAS INC - ANNOUNCED UPDATED DATA FROM DOSE ESCALATION PORTION OF COMPANY'S PHASE 1/2 CLINICAL TRIAL OF ARV-110 * ARVINAS INC - UPDATED DATA SHOWS AR DEGRADATION DEMONSTRATES THAT ARV-110 IS ...

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated ...